Navigation Links
Grupo Casa Saba Quarterly Earnings Report 3Q08
Date:10/28/2008

3% due to an increase in sales to the Instituto Mexicano del Seguro Social ("IMSS"), or the Mexican Social Security Institute, as well as the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado ("ISSSTE"), or the Mexican Social Security and Service Institute for Government Employees.

Publication sales decreased 11.23%, primarily as a result of lower unit sales. This decrease was due to the fact that Citem stopped distributing some publications that did not meet our minimal profitability requirements.

The sales mix did not change significantly this quarter. Private Pharma sales represented 83.88% of total sales (compared to 83.27% during the third quarter of 2007), while Government Pharma accounted for 3.83% (versus 3.46% during the third quarter of 2007). Health, Beauty, Consumer Goods, General Merchandise and Other represented 9.20% (compared to 9.33% in the third quarter of 2007) and Publications made up the remaining 3.09% (versus 3.94% during the third quarter of 2007).

SALES BY DIVISION

PRIVATE PHARMA

Sales in our Private Pharma division rose 13.89% during the third quarter of 2008, as a result of the consolidation of investments that were made within the sector during the past several months. This includes the most recent acquisition of Drogasmil Medicamento e Perfumeria, S.A., a Brazilian pharmacy chain.

Sales reached $5,604.89 million and represented 83.88% of the Group's total sales.

GOVERNMENT PHARMA

Sales in our Government Pharma division grew 25.13% due to an increase in sales to the Instituto Mexicano del Seguro Social ("IMSS") as well as the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado ("ISSSTE").

Government Pharma sales reached $256.13 million during 3Q08 and accounted for 3.83% of our total sales.

HEALTH, BEAUTY, CONSUMER GOODS, GENERAL MERCHANDISE AND OTHER

Sales in our Health, Beauty, Consumer Goods, General Merch
'/>"/>

SOURCE Grupo Casa Saba, S.A. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
2. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
3. Grupo Casa Saba Announces Fourth Quarter 2007 Results
4. Grupo Casa Saba Announces Third Quarter 2007 Results
5. NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
6. Infinity Property and Casualty Corporation Declares Quarterly Dividend
7. Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000
8. Robbins & Myers Announces Regular Quarterly Cash Dividend
9. West Increases Quarterly Dividend
10. Abbott Declares 339th Consecutive Quarterly Dividend
11. Emageon Files Quarterly Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... (HealthDay News) -- The tragic death from "rat-bite fever" of ... the pet rodents, according to a report from the U.S. ... a rare but potentially fatal illness that should be considered ... a history of rodent exposure is reported," said a team ... Service. The case outlined in the report occurred in ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... BRUNSWICK, N.J. Researchers at Rutgers Ernest Mario School ... the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory ... the transition of early prostate cancer to its more ... is the second leading cause of cancer death in ...
... Cancer Center at Thomas Jefferson University in Philadelphia ... pressure medications might help prevent the spread of ... that one type of pressure-lowering drug called an ... and causes cell death. , In earlier work ...
... discovered evidence that a series of genetic mutations work ... often-fatal form of acute lymphoblastic leukemia (ALL). , These ... of a gene, IKZF1, whose protein, Ikaros, normally helps ... a lymphocyte. The researchers also found that loss of ...
... Patented OwnCode(R) Consumer Heart Rate Monitor Technology Now Available in ... ... 2008 Polar, the leader in,heart rate monitoring and fitness ... only available in,Polar heart rate monitors -- can now be ...
... Calif., April 14 HealthFusion, a,national ... recognized for,call center operation customer satisfaction ... Certified Call Center Program(SM). This distinction,acknowledges ... call center,operations to provide "An Outstanding ...
... Galien USA 2008 Announced for September 24, Nominations ... Nobel Laureate Walter,Gilbert, Ph.D., the Carl M. Loeb ... Biogen, has joined fellow Nobel Laureates on the,committee ... research. Prix Galien USA 2008,( http://www.prix-galien-usa.com ) will ...
Cached Medicine News:Health News:Celebrex-Lipitor combo may halt prostate cancer 2Health News:Celebrex-Lipitor combo may halt prostate cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 3Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2